From GlobeNewswire: 2025-04-28 16:36:00

Tevogen Bio Holdings Inc. reaffirms its revenue forecast, projecting $1 billion in oncology pipeline revenue in its launch year and $10-14 billion over 5 years. The company’s unique drug development model aims for sustainable medical innovation, reflecting its commitment to patient accessibility. Tevogen recently secured up to $50 million for a dedicated R&D and manufacturing facility through an agreement with CD 8 Technology Services LLC, with no impact on shareholder equity. CEO Ryan Saadi looks forward to updating shareholders on forecasts and internal assets valuation as the company continues to build U.S.-based cell therapy manufacturing capabilities.



Read more at GlobeNewswire: Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1